Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-06-20 pm EDT After market 06:56:45 pm
68.49 USD +8.46% Intraday chart for Gilead Sciences, Inc. 68.1 -0.57%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Equity Markets Close Mixed as Investors Weigh Economic Data MT
Equity Markets Close Mixed After Macro Data MT
Health Care Stocks Rise Behind Gilead -- Health Care Roundup DJ
US Equities Markets Close Mixed Thursday as Markets Parse Latest Economic Data MT
Sector Update: Health Care Stocks Higher Late Afternoon MT
Sector Update: Health Care Stocks Mixed Thursday Afternoon MT
Equity Markets Mixed as Traders Weigh Macro Data MT
Sliding Technology Stocks Push S&P 500, Nasdaq Composite Lower MT
Sector Update: Health Care MT
Gilead Sciences' Twice-Yearly Shot Prevents 100% of HIV Cases in Trial, Shares Jump MT
US Benchmark Stock Indexes Mixed in Midday Trading MT
Gilead Sciences' Lenacapavir Shows 100% Efficacy, Superiority to Truvada For HIV Prevention MT
Gilead Sciences HIV Prevention Treatment Shows 100% Effectiveness in Phase 3 Trial DJ
Gilead's long-acting HIV drug superior to daily pill Truvada in study RE
Assembly Biosciences, Inc. announced that it has received $2.77507 million in funding from Gilead Sciences, Inc. CI
Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup DJ
EU regulator mandates label updates on CAR-T cancer therapies RE
Gilead Sciences' Kite Unit Reports Positive Data From New Analyses of Yescarta MT
Kite Announces Clinical Research and Real-World Evidence for Yescarta Demonstrate Benefit From Earlier Lines of Treatment CI
Transcript : Gilead Sciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:20 PM
Arcus Completes Enrollment in Phase 3 Trial of Domvanalimab-Containing Regimen for Stomach Cancer MT
Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA MT
Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study CI
Transcript : Gilead Sciences, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 11:00 AM
Gilead Sciences Says Investigational Chronic Liver Disease Drug Shows 'Sustained Efficacy' in Long-Term Trial MT
Chart Gilead Sciences, Inc.
More charts
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
68.49 USD
Average target price
82.7 USD
Spread / Average Target
+20.74%
Consensus
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. News Gilead Sciences, Inc.
  5. Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95